1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
AGING AND BONE QUALITY is sponsored by National Institute on Aging (NIA) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This program invites research applications to understand age-related changes in bone quality and their connection to increased bone fragility and susceptibility to osteoporotic fractures.
It seeks basic and clinical research to identify and evaluate the effects of age on factors related to bone quality and strategies to modify their impact on skeletal fragility and fracture susceptibility.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Applications may be submitted by foreign and domestic, non-profit and for-profit organizations, private and public such as colleges, universities, laboratories, units of state and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) awards (R29). Confirm the full requirements in the official notice before applying.
AGING AND BONE QUALITY is funded by National Institute on Aging (NIA) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article